Diferencia entre revisiones de «Tamsulosin»
(Add SMW Indications by Condition query table) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| Línea 52: | Línea 52: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
|mainlabel=- | |mainlabel=- | ||
Revisión actual - 21:56 20 mar 2026
Administration
- Type: α-blocker
- Dosage Forms:
- Routes of Administration: oral
- Common Trade Names: Flomax
Adult Dosing
- 0.4mg PO once daily or nightly
Urolithiasis
- 0.4mg PO QHS until stone expulsion
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
Renal Dosing
- Adult: No adjustment for CrCl >10
Hepatic Dosing
- Adult: No adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Retinal detachment
- Priapism
Common
- Headache, dizziness, insomnia, somnolence
- Abnormal ejaculation
- Rhinitis
- Back pain
Pharmacology
- Half-life: 9-15h
- Metabolism: CYP3A4 and CYP2D6
- Excretion: Mostly renal
Mechanism of Action
- α-1A antagonist→ smooth muscle relaxation in bladder neck, prostate, urethra→ increased urine flow rate
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute urinary retention | 0.4mg QHS | Alpha-blocker for BPH-related retention (outpatient) | PO | Adult |
| Urolithiasis | 0.4mg QHS | Medical expulsive therapy for stones 5-10mm | PO | Adult |